Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6ZN30
UPID:
BNC2_HUMAN
Alternative names:
-
Alternative UPACC:
Q6ZN30; B1APG9; Q6T3A3; Q8NAR2; Q9H6J0; Q9NXV0
Background:
Zinc finger protein basonuclin-2, a probable transcription factor specific for skin keratinocytes, plays a pivotal role in the differentiation of spermatozoa and oocytes. Its involvement in early urinary-tract development underscores its importance in cellular processes.
Therapeutic significance:
The association of Zinc finger protein basonuclin-2 with congenital lower urinary tract obstruction highlights its potential as a target for therapeutic intervention. Understanding the role of Zinc finger protein basonuclin-2 could open doors to potential therapeutic strategies.